Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

11/12/24 10:32:12 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $KRYS alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.9 KRYSTAL BIOTECH INC COMMON STOCK Cusip #501147102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #501147102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,291,926 Item 6: 0 Item 7: 4,292,881 Item 8: 0 Item 9: 4,292,881 Item 11: 14.942% Item 12: HC Cusip #501147102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,292,881 Item 8: 0 Item 9: 4,292,881 Item 11: 14.942% Item 12: IN Item 1(a). Name of Issuer: KRYSTAL BIOTECH INC Item 1(b). Address of Issuer's Principal Executive Offices: 2100 WHARTON STREET, SUITE 701 PITTSBURGH , PA 15203 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 501147102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,292,881 (b) Percent of Class: 14.942% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,292,881 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KRYSTAL BIOTECH INC. The interest of Select Biotechnology Portfolio, in the COMMON STOCK of KRYSTAL BIOTECH INC, amounted to 1,877,722 shares or 6.535% of the total outstanding COMMON STOCK at September 30, 2024. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of KRYSTAL BIOTECH INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $KRYS alert in real time by email

Recent Analyst Ratings for

$KRYS

Date	Price Target	Rating	Analyst
3/27/2026		Peer Perform	Wolfe Research
1/6/2026	$309.00	Neutral → Buy	Citigroup
3/5/2025	$245.00	Buy	Jefferies
8/6/2024	$195.00 → $204.00	Buy → Neutral	Citigroup
11/20/2023	$160.00	Buy	Goldman
10/24/2023	$100.00	Overweight	Cantor Fitzgerald
10/12/2023	$160.00	Buy	Citigroup
9/7/2023	$154.00	Buy	Berenberg

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

11/12/24 10:32:12 AM ET

$KRYS

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $KRYS alert in real time by email

Recent Analyst Ratings for

$KRYS

Date	Price Target	Rating	Analyst
3/27/2026		Peer Perform	Wolfe Research
1/6/2026	$309.00	Neutral → Buy	Citigroup
3/5/2025	$245.00	Buy	Jefferies
8/6/2024	$195.00 → $204.00	Buy → Neutral	Citigroup
11/20/2023	$160.00	Buy	Goldman
10/24/2023	$100.00	Overweight	Cantor Fitzgerald
10/12/2023	$160.00	Buy	Citigroup
9/7/2023	$154.00	Buy	Berenberg

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KRYS

Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$KRYS

$KRYS
Analyst Ratings

Wolfe Research initiated coverage on Krystal Biotech

Krystal Biotech upgraded by Citigroup with a new price target

Jefferies initiated coverage on Krystal Biotech with a new price target

$KRYS
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.

Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Krystal Biotech Inc.

$KRYS
Press Releases

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

$KRYS
Insider Trading

EVP, General Counsel Thomas John Charles sold $193,903 worth of shares (642 units at $302.03) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)

New insider Goux Laurent Louis Jean claimed ownership of 919 shares (SEC Form 3)

New insider Thomas John Charles claimed ownership of 642 shares (SEC Form 3)

$KRYS
FDA approvals

May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

$KRYS
Leadership Updates

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

$KRYS
Financials

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

$KRYS
Large Ownership Changes